Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OmniAb Inc OABI

Healthcare Biotechnology
OmniAb, Inc. offers a discovery platform that provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable the discovery of next-generation therapeutics. The OmniAb platform is the biological intelligence (BI) of transgenic animals, including OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to... see more

Recent & Breaking News (NDAQ:OABI)

Kuehn Law Encourages Investors of OmniAb, Inc. to Contact Law Firm

Newsfile 6 days ago

OmniAb Technologies Featured in Two Presentations at the 2024 Antibody Engineering & Therapeutics Conference

Business Wire December 16, 2024

OmniAb Reports Third Quarter 2024 Financial Results and Business Highlights

Business Wire November 12, 2024

OmniAb to Participate in Two Investor Conferences in November

Business Wire October 30, 2024

OmniAb to Report Third Quarter 2024 Financial Results on November 12

Business Wire October 22, 2024

OmniAb to Participate in Two Investor Conferences in September

Business Wire August 26, 2024

OmniAb Reports Second Quarter 2024 Financial Results and Business Highlights

Business Wire August 8, 2024

OmniAb to Report Second Quarter 2024 Financial Results on August 8

Business Wire July 25, 2024

OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology

Business Wire June 3, 2024

OmniAb to Participate in the Jefferies Global Healthcare Conference

Business Wire May 20, 2024

OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit

Business Wire May 15, 2024

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Business Wire May 9, 2024

OmniAb to Participate in Five Investor Conferences in May

Business Wire May 1, 2024

OmniAb to Report First Quarter 2024 Financial Results on May 9

Business Wire April 22, 2024

OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Business Wire March 20, 2024

OmniAb to Report Fourth Quarter 2023 Financial Results on March 20

Business Wire February 26, 2024

OmniAb to Participate in Two Investor Conferences in March

Business Wire February 20, 2024

OmniAb Presents New Scientific Data on its OmnidAb(TM) Platform at the 2023 Antibody Engineering & Therapeutics Conference

Business Wire December 14, 2023

OmniAb Highlights OmnidAb(TM) Launch and its Expanding Drug Discovery Platform at Today's Research & Technology Virtual Event

Business Wire November 9, 2023

OmniAb Reports Third Quarter 2023 Financial Results and Business Highlights

Business Wire November 9, 2023